Returning to Vienna marked an all-time record for Europe’s largest meeting for business development in life sciences. Read more »
It was standing room only for a BIO-Europe® panel discussion by four pharma licensing executives for some advice on how best to successfully position a drug development program for licensing, how to prepare the asset for dealmaking, how to make a program visible to buyers, what to say about it, and equally important, what not to say. Read more »
Patients have something to say about drug development, according to Tony Coles, former CEO for Onyx Pharmaceuticals.
Listening to patients earned Onyx USD 125 per share in cash from Amgen, the fifth largest biotechnology deal in history with a valuation of USD 10.4 billion. Read more »
In his role as vice chair for the European Technology Platform on Nanomedicine, Laurent Levy described the state of the emerging field of nano-therapeutics to set the context for a special workshop at BIO-Europe® 2013 asking, ” Is nano becoming the next sweet spot for drug development?” Read more »
The enthusiasm for biotech companies in public markets over the past year is in stark contrast to the caution of pharma companies in licensing deals. Read more »
Industry has increased the interest in acquisition of new drug assets and early stage technologies from academic research. Yet the administrative, communication, and cultural obstacles limit the ability of industry and academic institutions to effectively work together. Read more »
The regulatory and pricing paths for new drugs in the United States have become increasingly difficult to navigate. Due to outside policy pressures, the FDA is scrutinizing drugs more than in the past, requiring much more data. Even when a drug is approved, there is no guarantee that payers will cover its full cost, as they are starting to consider the drug’s overall value—improving quality of life and decreasing costs—along with its effectiveness. Read more »
As Head of Oncology/Immuno-oncology Partnering for Roche, Stefan Frings, MD, returns to BIO-Europe® seeking to extend the company’s portfolio. “We are keenly looking for best-in-disease opportunities and to strike deals.” Read more »
An online journal for executives in the life sciences, partneringNEWS™ is focused on the people behind the deals. Putting a human face to a collaboration agreement gives business development professionals the ability to get behind the headlines.
Sign up today to the free newsletter and never miss any new content.